The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-26 and is reviewed periodically as new material appears.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
While D-amino acid oxidase differs to some extent between various organisms, the structure is basically the same across most eukaryotes, excluding plants. This enzyme is a flavoprotein belonging to the FAD dependent oxidoreductase family, and acts on the CH−NH2 group of D-amino acid donors with oxygen as acceptor. It is also considered a peroxisomal enzyme containing FAD as a cofactor. Each DAO monomer has an FAD-binding domain (FBD) containing a Rossmann fold, and a substrate-binding domain (SBD) that also forms an interface with the other monomer in the protein. DAO exists as a dimer, with each monomer containing both an FBD and SBD. Each monomer is composed of 347 amino acids in human DAO, though among other eukaryotes the protein can range from 345 to 368 amino acids long. In human DAO, the two monomers are connected in a head-to-head fashion. DAO of other organisms, such as yeast, can be present as head-to-tail dimers. The hDAAO gene is found on chromosome 12 and contains 11 exons. DAO is capable of reducing oxygen quickly, and when reduced can stabilize anionic red semiquinone, and it is capable of forming a covalent bond with sulfites. These are all typical properties associated with flavoproteins. Human DAAO has slightly different properties from other DAAO molecules, including a weaker ability to bind FAD and decreased rate of reaction for some molecules, such as flavin.
The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse. Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. Other symptoms may include restlessness, increased sweating, and trouble sleeping. Less commonly there may be a feeling of the world spinning, numbness, or muscle pains. A randomised controlled trial compared maintenance therapy with gradual dose reduction or discontinuation among people with long-term psychosis. At 2 years, people in the reduction group were twice as likely to relapse (25%) as those in the maintenance group (13%). Moreover, those in the reduction group had no improvement in social functioning (a measure combining people's ability to look after themselves, work, study and take part in family and social activities), side effects, quality of life, symptoms, or bodyweight. There is evidence that withdrawal syndrome of antipsychotics can result in psychosis. This has occurred in patients who had previously no history of psychosis, but were taking antipsychotics for another reason. Tardive dyskinesia can also occur when the medication is stopped. Unexpected psychotic episodes have been observed in patients withdrawing from clozapine. This is referred to as supersensitivity psychosis, not to be equated with tardive dyskinesia. Tardive dyskinesia may abate during withdrawal from the antipsychotic agent, or it may persist.
=== Chemical industry === J. Peter Grace became CEO and president of Grace in 1945. Under the new leadership, the company began diversifying from the established shipping industry and Latin American operations that it had created. The company went from 60% of sales volume for Latin American operations in the 1950s to 19% of sale volume in 1962. In 1954, the company bought Davison Chemical Company (founded by William T. Davison) and the Dewey & Almy Chemical Company (founded in 1919 by Bradley Dewey and Charles Almy). Chemical sales growth went from 6% of sales in 1950 to 55% in 1977. When J. Peter Grace in 1978 was asked what may have been the best decision by the company, he stated the following:Well, I'd say buying Dewey & Almy. We paid $37 million when it was earning about $1.8 million, at about 20 times earnings. Today, its earning about $60 million.
Sources: en.wikipedia.org
Because of its limited availability and high cost, the 1H-MRS technique cannot be proposed for all children whose clinical condition suggests the diagnosis of brain creatine depletion. AGAT deficiency is, along with GAMT and creatine transporter defect, one of three inborn errors of the creatine biosynthesis/transport pathway. The prevalence of these defects is unknown, however they have been observed to occur in high frequency in intellectually disabled children. The actual genetic mutation associated with AGAT involves a tryptophan codon being converted to a stop codon at residue 149.
In March 2015, Spotlight entered into a purchase agreement with Memcine Pharmaceuticals, Inc., a Coralville, Iowa-based biotech company specializing in vaccine efficacy. Memcine Pharmaceuticals would officially become a Spotlight Innovation subsidiary in June 2015. In April 2015, Spotlight Innovation secured $2.5 million in financing from an unsecured convertible promissory note. In October 2016, Spotlight Innovation announced that it was discontinuing the Memcine Pharmaceuticals Immunoplex development program. In August 2016 Spotlight Innovation entered into a sponsored research agreement with Florida State University to support the work of Professor Hengli Tang in the development of treatments for Zika virus infection. In October 2016, Spotlight Innovation announced the formation of subsidiary Caretta Therapeutics, LLC. Caretta Therapeutics is based in Urbandale, Iowa. The subsidiary develops and markets over-the-counter (OTC) analgesic products formulated to provide relief from chronic pain associated with inflammation. In October 2016, Spotlight Innovation obtained an exclusive license from Indiana University Research and Technology Corp to commercialize an orally available small molecule named STL-182 with potential therapeutic potential for the treatment of spinal muscular atrophy. Early preclinical testing of STL-182 was accomplished by Dr. Elliot Androphy of Indiana University School of Medicine and Professor Kevin Hodgetts of Brigham and Women's Hospital.
=== Diet === Vitamin A, also known as retinoids, benefits the skin by normalizing keratinization, downregulating sebum production, which contributes to acne, and reversing and treating photodamage, striae, and cellulite. Vitamin D and analogues are used to downregulate the cutaneous immune system and epithelial proliferation while promoting differentiation. Vitamin C is an antioxidant that regulates collagen synthesis, forms barrier lipids, regenerates vitamin E, and provides photoprotection. Vitamin E is a membrane antioxidant that protects against oxidative damage caused most commonly in skin by UV rays.
=== Emergency treatment === Acute methamphetamine intoxication is largely managed by treating the symptoms and treatments may initially include administration of activated charcoal and sedation. There is not enough evidence on hemodialysis or peritoneal dialysis in cases of methamphetamine intoxication to determine their usefulness. Forced acid diuresis (e.g., with vitamin C) will increase methamphetamine excretion but is not recommended as it may increase the risk of aggravating acidosis, or cause seizures or rhabdomyolysis. Hypertension presents a risk for intracranial hemorrhage (i.e., bleeding in the brain) and, if severe, is typically treated with intravenous phentolamine or nitroprusside. Blood pressure often drops gradually following sufficient sedation with a benzodiazepine and providing a calming environment. Antipsychotics such as haloperidol are useful in treating agitation and psychosis from methamphetamine overdose. Beta blockers with lipophilic properties and CNS penetration such as metoprolol and labetalol may be useful for treating CNS and cardiovascular toxicity. The mixed alpha- and beta-blocker labetalol is especially useful for treatment of concomitant tachycardia and hypertension induced by methamphetamine. The phenomenon of "unopposed alpha stimulation" has not been reported with the use of beta-blockers for treatment of methamphetamine toxicity.
Sources: en.wikipedia.org
Oral mucosa heals faster than skin, suggesting that saliva may have properties that aid wound healing. Saliva contains cell-derived tissue factor, and many compounds that are antibacterial or promote healing. Salivary tissue factor, associated with microvesicles shed from cells in the mouth, promotes wound healing through the extrinsic blood coagulation cascade. The enzymes lysozyme and peroxidase, defensins, cystatins and an antibody, IgA, are all antibacterial. Thrombospondin and some other components are antiviral. A protease inhibitor, secretory leukocyte protease inhibitor, is present in saliva and is both antibacterial and antiviral, and a promoter of wound healing. Nitrates that are naturally found in saliva break down into nitric oxide on contact with skin, which will inhibit bacterial growth. Saliva contains growth factors such as epidermal growth factor, VEGF, TGF-β1, leptin, IGF-I, lysophosphatidic acid, hyaluronan and NGF, which all promote healing, although levels of EGF and NGF in humans are much lower than those in rats. In humans, histatins may play a larger role. As well as being growth factors, IGF-I and TGF-α induce antimicrobial peptides. Saliva also contains an analgesic, opiorphin. Licking will also tend to debride the wound and remove gross contamination from the affected area. In a recent study, scientists have confirmed through several experiments that the protein responsible for healing properties in human saliva is, in fact, histatin.
The United States, having become the only global superpower, used that ideological victory to reinforce its leadership position in the new world order, proclaiming that "the United States and its allies are on the right side of history." This new world order is referred to as "liberal hegemony" in international relations theory. Using the peace dividend, the United States Armed Forces were able to cut much of its expenditure, but the level rose again to comparable heights after the September 11 attacks and the initiation of the war on terror in 2001. Accompanying NATO expansion, Ballistic Missile Defense (BMD) systems were installed in Eastern Europe. However, from a relatively-weak developing country, China appeared as a fledgling emerging superpower that would challenge the U.S. and liberal democracy, creating new potential for worldwide conflict. In response to the rise of China, the U.S. has strategically "rebalanced" to the Asia-Pacific region, but also began to retreat from international commitments in favor of its own interests. Starting from the 2020s onward, the perceived threat of global terrorism in the post-9/11 era has expanded beyond Middle Eastern jihadist groups, culminating in the United States and Canada designating several drug cartels and transnational criminal organizations as terrorist organizations in the context of narcoterrorism and the war on drugs. The 2020s also found the Monroe Doctrine once again playing a central role in US foreign policy.
== Constitutional issues == Several of the convention's provisions are prefaced with the words, "Subject to its constitutional principles and the basic concepts of its legal system, each Party shall ..." According to Fazey, "This has been used by the USA not to implement part of article 3 of the 1988 Convention." Similarly, if a national prohibition on drug possession violated a nation's constitution, those provisions would not be binding on that country.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.